Amicus Therapeutics Inc


Market Cap$3.15B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Amicus Therapeutics IncAmicus Therapeutics Inc-21.40%-113%9.83

Target Price by Analysts

63.3% upsideAmicus Therapeutics Target Price DetailsTarget Price

Current Fair Value

28.8% upside

Undervalued by 28.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$3.15 Billion
Enterprise Value$3.30 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-0.49
Outstanding Shares296,198,963
Avg 30 Day Volume2,152,170


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-21.44
Price to Sales9.8
Price to Book Ratio-
Enterprise Value to Revenue7.8
Enterprise Value to EBIT-57.14
Enterprise Value to Net Income-23
Total Debt to Enterprise0.12
Debt to Equity2.97

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Amicus Therapeutics Inc

CEO: John Crowley